Treatment of iron deficiency anaemia from the nephrologist’s point of view

Česká verzia

Authors: M. Horáčková
Authors place of work: I. interní klinika 2. LF UK a FN v Motole, Praha
Published in the journal: Kardiol Rev Int Med 2014, 16(5): 374-378
Category: Cardiology Review

Summary

Renal anaemia is principally caused by erythropoietin deficiency. Chronic kidney disease is commonly accompanied by development of anaemia that is characterised by poor intestinal iron (Fe) absorption and low ferritin levels. Thus, anaemia with a sideropenic component requires erythropoietin as well as Fe supplementation. The effect of oral Fe preparations is limited by their reduced absorption rate and gastrointestinal side‑ effects. The introduction of second‑ generation intravenous Fe preparations (iron sucrose and ferric gluconate) reduces the risk of anaphylactic reactions but cannot be administered in large doses and the typical 1000 mg therapy requires several clinic visits. Ferric carboxymaltose offers an effective and rapid correction of iron deficiency. It can be administered in a large replenishment dose (1000 mg) over a short infusion period (15– 30 min), typically to the amount required for complete iron repletion.

Keywords:
renal anaemia – iron deficiency – iron therapy regimen

Zdroje

1. Caro J, Brown S, Miller O et al. Erythropoietin levels in uremic nephric an anephric patients. J Lab Clin Med 1979; 93: 449– 458.

2. Klener P. Přehled přípravků s erytropoetickopu aktivitou. Remedia 2011; 21: 265– 269.

3. Fairbenks VF, Beutler E. Iron metabolism. In: Wiliams Hematology. 5th ed. New York: McGraw‑ Hill Inc 1995: 369– 380.

4. Oates PS, Ahmed U. Molecular regulation of hepatic expression of iron regulatory hormone hepcidin. J Gastroenterol Hepatol 2007; 22: 1378– 1387.

5. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011– 1023.

6. Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother 2010; 65 (Suppl 3): 11– 24. doi: 10.1093/ jac/ dkq303.

7. Nidzielska I, Chudek J, Kowol I et al. The odontogenic‑related microinflammation in patients with chronic kidney disease. Ren Fail 2014; 36: 883– 888. doi: 10.3109/ 0886022X.2014.894764.

8. Van Wyck DB, Stivelman JC, Ruiz J et al. Iron status in patients receiving erythropoietin for dialysis‑associated anemia. Kidney Int 1989; 35: 712– 716.

9. Fishbane S, Mittal SK, Maesaka JK. Beneficial effect of iron therapy in renal failure patients on hemodialysis. Kidney Int Suppl 1999; 69: S67– S70.

10. Cavill I, MacDougall IC. Erythropoiesis and iron supply in patients treated with erythropoietin. Erythropoiesis 1992; 3: 50– 55.

11. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end‑stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73– 78.

12. MacDougall IC, Roberts DE, Neubert P et al. Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant human erythropoietin in patients on CAPD. Contrib Nephrol 1989; 76: 112– 121.

13. Singh AK, Szezech L, Tang KL et al. Correction of anemia with epoetin alpha in chronic kidney disease. N Engl J Med 2006; 355: 2085– 2098.

14. Drüeke TB, Locatelli T, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071– 2084.

15. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584– 590.

16. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471– 530.

17. National Kidney Foundation. KDIGO Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2012; 2: 283– 287.

18. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41– 46.

19. Sunder‑ Plassman G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070– 2076.

20. Locatelli F, Bárány P, Covic A et al. Kidney disease: Improving Global Outcome guidelines on anemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28: 1346– 1359. doi: 10.1093/ ndt/ gft033.

21. Hallberg L. Bioavailability of dietary iron in man. Annu Rev Nutr 1981; 1: 123– 147.

22. Kooistra MP, van Es A, Struyvenberg A et al. Low iron absorption in erythropoietin‑treated Hemodialysis patients. J Am Soc Nephrol 1995; 6: 543.

23. Donnelly SM, Posen GA, Ali MA. Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med 1991; 14: 271– 276.

24. Eschbach JW, Cook JD, Finch CA. Iron absorption in chronic renal disease. Clin Sci 1970; 38: 191– 196.

25. Schneider W. The fate of iron compounds in the gastrointestinal tract. Arzneimittelforschung 1987; 37: 92– 95.

26. Halberg I, Rittinger L, Solvell L. Side effects of oral iron therapy. A double‑blind study of different iron compounds in tablet form. Acta Med Scand Suppl 1966; 459: 3– 10.

27. Chertow GM, Mason PD, Vage‑ Nilsen O et al. Update on adverse events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378– 382.

28. Moore RA, Gaskell H, Rose P et al. Meta‑analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial and published trial data. BMC Blood Disorders 2011; 11: 1– 14. doi: 10.1186/ 1471‑ 2326‑ 11‑ 4.

29. Kalantar‑ Zadeh K, Lee GH. The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease? Clin J Am Nephrol 2006; 1 (Suppl 1): S1– S18.

30. Kalantar Zadeh K, Regidor DL, McAllister CJ et al. Time‑ dependent association between Fe and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070– 3080.

31. Bailie GR, Tong L, Li Y et al. Association of intravenous iron dosing with mortality: findings from DOPPS. ASN Kidney Week Abstract 2010. J Am Soc Nephrol 2010; 21: TH‑ FC041.

32. Kalantar‑ Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and Fe in hemodialysis patients. Nephrol Dial Transplant 2004; 19: 141– 149.

33. St Pierre TG, Clark PR, Chua‑ anusorn W et al. Noninvasive measurement and imaging of liver Fe concentration using proton magnetic resonance. Blood 2005; 105: 855– 861.

34. Ferrari P, Kulkarni H, Dheda S et al. Serum iron markers inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 77– 83. doi: 10.2215/ CJN.04190510.

35. Macdougal IC, Bock AH, Carrera F et al. FIND‑ CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anemia. Nephrol Dial Transplant 2014. [In press]